BIBF 1120 ES

DRUG2 trials

Sponsors

Boehringer Ingelheim

Conditions

HealthyMultiple Myeloma

Phase 1

An Dose Escalation Study of BIBF 1120 Administered in Patients With Relapsed or Refractory Multiple Myeloma

CompletedNCT02182141

Boehringer IngelheimMultiple Myeloma

Start: 2003-04-30Updated: 2014-07-18

Metabolism and Pharmacokinetics of [14C]-BIBF 1120 in Healthy Male Volunteers

CompletedNCT02182154

Boehringer IngelheimHealthy

Start: 2005-10-31Updated: 2014-07-18